BICYCLE THERAPEUTICS plc
For the period ended Mar 31, 2024. Filed May 2, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 2, 2024
BCYC$3.77+4.4%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
(In thousands, except share and per share data)
| | | | | | | |
|---|---|---|---|---|---|---|
| · · March 31, · · December 31, | ||||||
| · 2024 · 2023 | ||||||
| Assets · · | ||||||
| Current assets: · · | ||||||
| Cash and cash equivalents | | $456,997 | | $526,423 | ||
| Prepaid expenses and other current assets | | 19,903 | | 11,406 | ||
| Research and development incentives receivable | | 39,062 | | 24,039 | ||
| Total current assets | | 515,962 | | 561,868 | ||
| Property and equipment, net | | 12,788 | | 14,515 | ||
| Operating lease right-of-use assets | | 12,025 | | 13,169 | ||
| Other assets | | 6,368 | | 5,792 | ||
| Total assets | | $547,143 | | $595,344 | ||
| Liabilities and shareholders’ equity | | | ||||
| Current liabilities: | | | | | ||
| Accounts payable | | $7,061 | | $13,050 | ||
| Accrued expenses and other current liabilities | | 26,029 | | 31,509 | ||
| Deferred revenue, current portion | | 16,420 | | 24,978 | ||
| Total current liabilities | | 49,510 | | 69,537 | ||
| Long-term debt, net of discount | | | 30,802 | | | 30,698 |
| Operating lease liabilities, net of current portion | | 8,048 | | 9,382 | ||
| Deferred revenue, net of current portion | | | 98,127 | | | 110,216 |
| Other long‑term liabilities | | 4,608 | | 4,579 | ||
| Total liabilities | | 191,095 | | 224,412 | ||
| Commitments and contingencies (Note 11) | | | ||||
| Shareholders’ equity: | | | ||||
| Ordinary shares, including non-voting ordinary shares, £0.01 nominal value; 61,876,165 and 59,612,613 shares authorized on March 31, 2024 and December 31, 2023, respectively; 42,632,597 and 42,431,766 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively | | 553 | | 550 | ||
| Additional paid-in capital | | 894,596 | | 883,446 | ||
| Accumulated other comprehensive loss | | (778) | | (1,304) | ||
| Accumulated deficit | | (538,323) | | (511,760) | ||
| Total shareholders’ equity | | 356,048 | | 370,932 | ||
| Total liabilities and shareholders’ equity | | $547,143 | | $595,344 | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.